YANCHENG, JIANGSU, CHILE, January 7, 2026 /EINPresswire.com/ -- In the face of increasingly demanding industrial and ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...

The 2025 USA Rice Outlook Conference featured a discussion on the OBBBA, highlighting its impact on conservation and crop ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

In this segment, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, provides a corporate ...

Full conversion of convertible notes reduces long-term liabilities, removes potential equity overhang, and helps position SMX ...

Nutrition recommendations the US government released Wednesday are set to play a key role influencing regulatory changes and federally funded programs that determine what food tens of millions of ...

There are institutions whose decline happens so gradually that, one day, the public simply wakes up to a painful conclusion: ...

Prior to starting his own business, Mark served as the Technical Editor on EC&M for six years, worked three years in nuclear ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-'408TEV-' ...

Discover the top 3 undervalued Hotels, Restaurants & Leisure stocks for Wednesday, January 07 based on AAII’s Stock Grades.